Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (946 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Summarizing techniques used to describe the pattern of mortality and survival in populations. These methods can be applied to the study not only of death, but also of any defined endpoint such as the onset of disease or the occurrence of disease complications.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Life Table; Tables, Life; Life Table Analysis; Analyses, Life Table; Analysis, Life Table; Life Table Analyses; Life Table Estimates; Estimate, Life Table.
Where it fits in the MeSH classification
- Broader topics
- Life Expectancy; Actuarial Analysis
Research landscape
PubMed indexes 6,742 records tagged with the MeSH heading “Life Tables” (counts retrieved 2026-10-29). 304 of them (4.5%) were published from 2020 onward, and the busiest period so far is through 1999 with 3,466 records.
Reviews account for 451 records (6.7%) and meta-analyses for 31. Randomized controlled trials number 487 (7.2%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 3,466 |
| 2000-2009 | 2,191 |
| 2010-2019 | 781 |
| 2020 onward | 304 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 451 | 6.7% |
| Meta-analyses | 31 | 0.5% |
| Randomized controlled trials | 487 | 7.2% |
Method: PubMed query "Life Tables"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in clinical research
Research methods determine how much a result can be trusted. Randomized trials guard against confounding, systematic reviews and meta-analyses combine many studies, and observational designs are valuable but can show only association. Reporting standards, trial registration and pre-specified outcomes reduce bias. When reading about a method, ask what problem it is designed to solve and which problems it does not solve.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies [1]
Abstract reading summary — source excerpts
- Opening excerpt
- ObjectivesTo determine what thresholds are most often cited in the cost-effectiveness literature for low- and middle-income countries (LMICs), given various recommendations proposed and used in the literature to date, and thereafter to assess whether studies appropriately justified their use of threshold values.
- Closing excerpt
- Rather than rely on commonly used, generic economic thresholds, we encourage authors to use context-specific thresholds that reflect local preferences.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (191 words)
ObjectivesTo determine what thresholds are most often cited in the cost-effectiveness literature for low- and middle-income countries (LMICs), given various recommendations proposed and used in the literature to date, and thereafter to assess whether studies appropriately justified their use of threshold values.MethodsWe reviewed the contents of the Tufts Medical Center Global Health Cost-Effectiveness Analysis Registry, a repository of all English language cost-per-disability-adjusted life-year averted studies indexed in PubMed. Our review included all catalogued cost-per-disability-adjusted life-year studies published from 2000 through 2015. We restricted attention to studies that investigated interventions in LMICs.ResultsOur analysis identified 381 studies (80%) focused on LMICs. Of these studies, 250 (66%) cited the World Health Organization's 1 to 3 times gross domestic product per capita threshold. A full-text review of 60 (24%) of these articles (randomly selected) revealed that none justified use of this threshold in the particular country or countries studied beyond citing (generic) guideline documents.ConclusionsCost-effectiveness analysis can help inform health care spending, but its value depends on incorporating assumptions that are valid for the applicable setting. Rather than rely on commonly used, generic economic thresholds, we encourage authors to use context-specific thresholds that reflect local preferences.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30005746 · DOI · PMC6041503
Integrating temperature-dependent life table data into a matrix projection model for Drosophila suzukii population estimation [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Temperature-dependent fecundity and survival data was integrated into a matrix population model to describe relative Drosophila suzukii Matsumura (Diptera: Drosophilidae) population increase and age structure based on environmental conditions.
- Closing excerpt
- suzukii populations.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (244 words)
Temperature-dependent fecundity and survival data was integrated into a matrix population model to describe relative Drosophila suzukii Matsumura (Diptera: Drosophilidae) population increase and age structure based on environmental conditions. This novel modification of the classic Leslie matrix population model is presented as a way to examine how insect populations interact with the environment, and has application as a predictor of population density. For D. suzukii, we examined model implications for pest pressure on crops. As case studies, we examined model predictions in three small fruit production regions in the United States (US) and one in Italy. These production regions have distinctly different climates. In general, patterns of adult D. suzukii trap activity broadly mimicked seasonal population levels predicted by the model using only temperature data. Age structure of estimated populations suggest that trap and fruit infestation data are of limited value and are insufficient for model validation. Thus, we suggest alternative experiments for validation. The model is advantageous in that it provides stage-specific population estimation, which can potentially guide management strategies and provide unique opportunities to simulate stage-specific management effects such as insecticide applications or the effect of biological control on a specific life-stage. The two factors that drive initiation of the model are suitable temperatures (biofix) and availability of a suitable host medium (fruit). Although there are many factors affecting population dynamics of D. suzukii in the field, temperature-dependent survival and reproduction are believed to be the main drivers for D. suzukii populations.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25192013 · DOI · PMC4156384
Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundSpinal muscular atrophy (SMA) is a progressive, devastating disease and a leading inherited cause of infant mortality.
- Closing excerpt
- ConclusionsIn the absence of a survey or other means to directly estimate prevalence in the US population, estimates can be calculated indirectly using a life table.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (259 words)
BackgroundSpinal muscular atrophy (SMA) is a progressive, devastating disease and a leading inherited cause of infant mortality. The limited population-based literature is confined to small regional studies. Estimates of prevalence are needed to characterize the burden of SMA and to understand trends in prevalence by disease type as new treatments become available. The reported estimates of SMA genotype prevalence at birth consistently range from 8.5-10.3 per 100,000 live births, with a mid-range estimate of 9.4 per 100,000. Among infants born with an SMA genotype, it is reported that ~58% will develop SMA Type I, 29% will develop Type II, and 13% will develop Type III, respectively.ResultsUsing evidence from peer-reviewed literature for SMA birth prevalence, age at symptom onset, and SMA type-specific survival, and incorporating United States vital statistics, we constructed life tables to estimate prevalence for SMA Types I, II, and III in the United States. We estimated the number of prevalent cases in the US to be 8526, 9429, and 10,333 based on a birth prevalence of 8.5, 9.4, and 10.3, respectively (the lower, midpoint, and upper ends of the reported range). Assuming the midpoint of 9.4 and US-reported survival, the type-specific population prevalence estimates were 1610 for SMA Type I, 3944 for SMA Type II, and 3875 for SMA Type III. Evidence-based estimates of the number of people living with SMA in the United States in the published literature were previously unavailable.ConclusionsIn the absence of a survey or other means to directly estimate prevalence in the US population, estimates can be calculated indirectly using a life table.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29183396 · DOI · PMC5704427
Use of mortality tables by level of deprivation in the study of social inequalities in cancer survival [4]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundPrevious studies have reported lower net survival probabilities for socioeconomically deprived patients, using non-deprivation specific lifetables.
- Closing excerpt
- Development of such deprivation-specific lifetables for future years is crucial to understand mechanisms of social inequalities and work towards reducing the social burden.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (252 words)
BackgroundPrevious studies have reported lower net survival probabilities for socioeconomically deprived patients, using non-deprivation specific lifetables. Not accounting for the social gradient in background mortality could potentially overestimate the effect of deprivation on net survival. The aim of this study was to estimate the impact of taking into account the social gradient of expected mortality in the general population on the study of the social gradient of survival of people with cancer.MethodsFrench cancer registry data was analyzed, with 190,902 incident cases of nineteen cancer sites between 2013 and 2015. Deprivation was measured using the European deprivation index (EDI). Net survival was estimated thanks to additive models with French lifetables stratified on deprivation level with the EDI, using the non-parametric Pohar-perme method and flexible excess hazard modelling with multidimensional penalized splines, firstly with non-specific lifetables then with the deprivation specific-lifetables.ResultsA significant effect of EDI on excess mortality hazard (EMH) remained when using the deprivation-specific lifetables for colorectal, lung cancer and melanoma in both sexes, and esophagus, bladder, head and neck and liver cancer for men, and breast, cervix and uterine cancer for women. The only site where the effect of EDI on EMH was no longer significant when using deprivation-specific lifetables was prostate cancer.ConclusionsThe use of deprivation-specific lifetables confirms the existence of a social gradient in cancer survival, indicating that these inequalities do not result from inequalities in background mortality. Development of such deprivation-specific lifetables for future years is crucial to understand mechanisms of social inequalities and work towards reducing the social burden.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39912859 · DOI · PMC12018625
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Racial and ethnic disparities in birth outcomes: a life-course perspective [5]
- Research article A systematic review to calculate background miscarriage rates using life table analysis [6]
- Research article Life years lost among patients with a given disease [7]
- Research article Life table (survival) analysis to generate cumulative pregnancy rates in assisted reproduction: are we overestimating our success rates? [8]
- Research article Before senescence: the evolutionary demography of ontogenesis [9]
- Research article Diabetic angiopathy in children [10]
References
- Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. . 2018. PMID 30005746 · DOI · PMC6041503
- Wiman NG, Walton VM, Dalton DT, Anfora G, Burrack HJ, Chiu JC, et al.. Integrating temperature-dependent life table data into a matrix projection model for Drosophila suzukii population estimation. . 2014. PMID 25192013 · DOI · PMC4156384
- Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. . 2017. PMID 29183396 · DOI · PMC5704427
- Wilson S, Merville O, Dejardin O, Gardy J, Rollet Q, Jooste V, et al.. Use of mortality tables by level of deprivation in the study of social inequalities in cancer survival. . 2025. PMID 39912859 · DOI · PMC12018625
- Lu MC, Halfon N. Racial and ethnic disparities in birth outcomes: a life-course perspective. Matern Child Health J. 2003. PMID 12710797 · DOI
- Ammon Avalos L, Galindo C, Li DK. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol. 2012. PMID 22511535 · DOI
- Andersen PK. Life years lost among patients with a given disease. Stat Med. 2017. PMID 28585255 · DOI
- Daya S. Life table (survival) analysis to generate cumulative pregnancy rates in assisted reproduction: are we overestimating our success rates?. Hum Reprod. 2005. PMID 15790603 · DOI
- Levitis DA. Before senescence: the evolutionary demography of ontogenesis. Proc Biol Sci. 2011. PMID 21123273 · DOI · PMC3049054
- Danne T, Kordonouri O, Hövener G, Weber B. Diabetic angiopathy in children. Diabet Med. 1997. PMID 9455928 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.